SLXN — Silexion Therapeutics Ltd.
$0.1888+14.29%
Last close: · regular session
After-hours $0.1699 -10.01% ·
Last 60 sessions
Opening the full analysis uses 1 of your 3 free tickers today.
Chart, dilution, float and news for SLXN in the TickerWise workspace.
Silexion Therapeutics LTD is a biopharmaceutical company specializing in the discovery and advancement of RNA interference (RNAi)-based cancer therapies and their associated delivery systems, with a focus on treating aggressive solid tumors. The company's strategy for addressing these tumors relies on its proprietary LODER delivery platform. Its product pipeline features several key candidates: SiG12D-LODER, which has progressed through both preclinical studies and an open-label Phase I clinical trial for pancreatic cancer; Prostate-LODER, currently undergoing preclinical evaluation for prostate cancer; and GBM-LODER, also in preclinical development, targeting Glioblastoma Multiforme, a highly malignant primary brain tumor. Founded in 2008, Silexion Therapeutics is headquartered in Jerusalem, Israel.
Company profile
- Sector: Healthcare
- Industry: Biotechnology
- Country: IL
- Exchange: NASDAQ Global Market
- Employees: 11
- Website: https://silexion.com
Latest SEC filings for SLXN
Latest SLXN news
- Silexion Therapeutics Announces First Patient Successfully Dosed in Phase 2/3 Clinical Trial of SIL204 in Locally Advanced Pancreatic Cancer Read article
- Silexion Therapeutics Announces Exercise of Warrants Read article
- Silexion Therapeutics (SLXN) Stock Soars 61% After Hours: Here's What's Going On
- Silexion Highlights Positive Translational Data for RNAi Oncology
- Form 8K Silexion Therapeutics Corp For: 28 September By Investing.com
- Silexion reports preclinical data on SIL204 delivery mechanism By Investing.com
- Silexion Therapeutics Reports Positive Preclinical Findings for SIL204, Demonstrating Key Mechanism for Endogenous Systemic Uptake in KRAS-Driven Cancers Read article
- Price to sales forward of Silexion Therapeutics Corp
Opening the full analysis uses 1 of your 3 free tickers today.
Educational tool only — not investment advice.